Core Viewpoint - GlaxoSmithKline has agreed to acquire Canadian biotech company 35Pharma for $950 million in cash, marking the second significant transaction under new CEO Luke Miels aimed at accelerating new drug development [1] Group 1: Acquisition Details - The acquisition price for 35Pharma is $950 million [1] - This transaction is part of GlaxoSmithKline's strategy to enhance its respiratory drug pipeline [1] Group 2: Strategic Implications - The experimental pulmonary hypertension drug HS235 from 35Pharma will strengthen GlaxoSmithKline's future respiratory drug offerings [1]